Review

Incretin Therapy - Present and Future

Alan J. Garber

Manuscript submitted June 30, 2011; resubmitted October 10, 2011; accepted October 22, 2011.

Keywords: type 2 diabetes, hypoglycemia, glycemic control, antidiabetic, incretin, GLP-1, DPP-4, GLP-1 receptor agonist, prediabetes

Abstract

Although newer treatments for type 2 diabetes (T2D) patients have produced continual improvements in outcome, a large and growing population with prediabetes remains under-treated. In the last few years, incretin-based therapies have become an important treatment option for patients with T2D. There are two classes of incretin agents: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon like peptide 1 (GLP-1) receptor agonists. The ultimate goal of agents within both of these classes is to increase GLP-1 signaling, which results in augmented glucose-induced insulin secretion, inhibition of glucagon secretion, and decreased appetite. This should result in improved regulation of glucose homeostasis. GLP-1 receptor agonists enable patients to achieve significant weight loss. In contrast, DPP-4 inhibitors result in a less dramatic increase in GLP-1 levels; therefore, they are weight neutral. Incretin therapies are currently recommended for use early in the treatment algorithm for T2D patients whose disease is not manageable by diet and exercise alone, but the potential for these agents may be farther reaching. Current studies are evaluating the potential benefits of combining incretin therapies with basal insulin to provide continuous glucose control before and after meals. In addition, these agents may be promising for patients with prediabetes since they effectively reduce glycosylated hemoglobin levels and fasting plasma glucose levels, enable weight control, and have the potential to preserve β-cell function. Clearly, all of these properties are desirable for patients with prediabetes.

Fulltext: HTML , PDF (2.9 MB)

This article has been cited by other articles:

	Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Pre-Diabetes to Type 2 Diabetes Garber A Endocr Pract 2015. 25:1-39
	Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility Wessel J, Chu AY, Willems SM, Wang S, Yaghootkar H, Brody JA, Dauriz M, Hivert MF, Raghavan S, Lipovich L, et al. Nat Commun 2015. 6:5897
	Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study Terauchi Y, Satoi Y, Takeuchi M, Imaoka T Endocr J 2014. 61(10):949-959
	Alogliptin benzoate for the treatment of type 2 diabetes Seino Y, Yabe D Expert Opin Pharmacother 2014. 15(6):851-863
	Benefits of healthy adipose tissue in the treatment of diabetes Gunawardana SC World J Diabetes 2014. 5(4):420-430
	Potential of pharmacological modulation of level and activity of incretins in diabetes mellitus type 2 Spasov AA, Chepljaeva NI Biochem (Moscow) Suppl Series B Biomed Chem 2014. 8(4):293-301
	Call-to-action: timely and appropriate treatment for people with type 2 diabetes in Latin America Escalante M, Gagliardino JJ, Guzman JR, Tschiedel B Diabetes Res Clin Pract 2014. 104(3):343-352
	A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1 Zhang J, Xue C, Zhu T, Vivekanandan A, Pennathur S, Ma ZA, Chen YE Plos One 2013. 8(12):e83509
	Adipose tissue, hormones, and treatment of type 1 diabetes Gunawardana SC Curr Diabetes Rep 2012. 12(5):542-550
	The alpha-cell as target for type 2 diabetes therapy Christensen M, Bagger JI, Vilsboll T, Knop F Rev Diabet Stud 2011. 8(3):369-381
	The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS Special Issue Raz I, Gallwitz B Rev Diabet Stud 2011. 8(3):288-292